(Q39398836)

11 September 2017

title

Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines (English)

1 reference

11 September 2017

0 references

1 reference

Nathalie Rioux-Leclercq

9

object named as

Nathalie Rioux-Leclercq

1 reference

11 September 2017

Julien Edeline

2

0 references

Jean-Jacques Patard

3

object named as

Jean-Jacques Patard

1 reference

11 September 2017

Bénédicte Martin

1

1 reference

11 September 2017

Emmanuel Oger

4

1 reference

11 September 2017

Florence Jouan

5

1 reference

11 September 2017

Gaëlla Boulanger

6

1 reference

11 September 2017

Sélim Zerrouki

7

1 reference

11 September 2017

Cécile Vigneau

8

1 reference

11 September 2017

language of work or name

1 reference

10 February 2012

1 reference

Journal of Cancer Research and Clinical Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

138

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

907-916

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-012-1162-x

11 September 2017

exact match

0 references

cites work

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Alterations in VHL as potential biomarkers in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Tumour suppression by the human von Hippel-Lindau gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

From theoretical synergy to clinical supra-additive toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Combination targeted therapy in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

12 December 2020

Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells

1 reference

12 December 2020

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

1 reference

12 December 2020

10.1007/S00432-012-1162-X

Identifiers

DOI

1 reference

11 September 2017

1 reference